Tag: clinical trial
-
AI-Powered App Matches Human-Led Diabetes Prevention Programs in Prediabetes Trial
AI-Powered Diabetes Prevention: A Milestone in Prediabetes Care A landmark randomized trial from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health shows that an AI-powered lifestyle intervention app can reduce the risk of developing type 2 diabetes in adults with prediabetes at rates comparable to traditional, human-led programs. Published in JAMA…
-
AI-Powered Diabetes Prevention: AI DPP Matches Human-Led Programs
Unlocking Equal Ground: AI-Driven DPP Learning from Real-World Trials In a landmark study, researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report that an AI-powered lifestyle intervention app for prediabetes reduced diabetes risk at rates comparable to traditional, human-led programs. The work, funded by the National Institutes of Health…
-
Portlaoise Boy’s Life-Changing ADA-SCID Gene Therapy Trial Results
Life-Changing Breakthrough for Portlaoise Boy in ADA-SCID Gene Therapy Trial A nine-year-old boy from Portlaoise, Ireland, has witnessed transformative improvements after participating in a landmark medical study targeting ADA-SCID, a rare and life-threatening immune system disorder. The trial, conducted in part at Great Ormond Street Hospital (GOSH) in London, represents a significant milestone in the…
-
Portlaoise Boy’s Landmark Gene Therapy Trial Delivers Life-Changing Results
Groundbreaking trial offers new hope for ADA-SCID patients The story of a nine-year-old boy from Portlaoise who took part in a landmark medical study has offered a beacon of hope for children with ADA-SCID, a rare and life-threatening immune deficiency. After being diagnosed just three weeks old, his family faced a long and difficult journey…
-
Portlaoise Boy Finds Life-Changing Cure Through Groundbreaking ADA-SCID Gene Therapy
Groundbreaking Gene Therapy Brings New Hope for ADA-SCID Patients A nine-year-old boy from Portlaoise, Ireland, has become one of the most compelling success stories in recent medical research after participating in a landmark gene therapy trial. Andy Cash, diagnosed with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) as a newborn, has seen transformative improvements that his…
-
Portlaoise Boy’s Life-Changing Recovery from Landmark ADA-SCID Gene Therapy Trial
Portlaoise boy’s journey from isolation to normal life A nine-year-old boy from Portlaoise, Ireland, has experienced what clinicians are calling life-changing results after taking part in a landmark gene therapy trial for ADA-SCID. Diagnosed just three weeks after birth, the boy faced a condition that leaves children with virtually no immune system, making everyday activities…
-
Landmark ADA-SCID gene therapy delivers life-changing results for Portlaoise boy
Overview: a breakthrough in ADA-SCID treatment A Portlaoise boy’s participation in a landmark medical study has yielded life-changing results, offering new hope for children born with the rare immune condition ADA-SCID. The nine-year-old, Andy Cash, was diagnosed with the life-threatening disorder just weeks after birth, and his family faced a long, difficult journey before a…
-
ADA-SCID Gene Therapy Shows Long-Term Success in Children
Breakthrough in pediatric ADA-SCID treatment A large international study led by researchers from Great Ormond Street Hospital (GOSH), University College London (UCL), and the University of California, Los Angeles (UCLA) has demonstrated the long-term safety and effectiveness of a standard lentiviral gene therapy for ADA-SCID, a rare and life-threatening immune disorder. The cohort, followed for…
-
Experimental gene therapy restores immune system function in ADA-SCID children
Groundbreaking therapy offers durable immune restoration for ADA-SCID An experimental gene therapy developed by researchers at UCLA, University College London (UCL) and Great Ormond Street Hospital (GOSH) has achieved durable restoration of immune system function in 59 of 62 children born with ADA-SCID, a rare and often deadly genetic immune disorder. The long-term follow-up results,…
-
Experimental Gene Therapy Restores Immune Function in Children with ADA-SCID
Breakthrough in ADA-SCID treatment: Gene therapy shows lasting immune restoration Researchers have reported a landmark advance in treating ADA-SCID, a life-threatening genetic immune disorder. An experimental gene therapy developed by teams at UCLA, University College London (UCL), and Great Ormond Street Hospital (GOSH) restored and sustained immune system function in 59 of 62 children born…